Association of hyperdense middle cerebral artery sign with clinical outcome in patients treated with tissue plasminogen activator

Claude Manelfe, Vincent Larrue, Rüdiger Von Kummer, Luigi Bozzao, Peter Ringleb, Stefano Bastianello, Françoise Iweins, Emmanuel Lesaffre

Research output: Contribution to journalArticle

Abstract

Background and Purpose-The hyperdense middle cerebral artery sign (HMCAS) is a marker of thrombus in the middle cerebral artery. The aim of our study was to find out the frequency of the HMCAS, its association with initial neurological severity and early parenchymal ischemic changes on CT, its relevance to clinical outcome, and the efficacy of intravenous recombinant tissue plasminogen activator (rtPA) in patients with the HMCAS. Methods-Secondary analysis of the data from 620 patients who received either rtPA or placebo in the European Cooperative Acute Stroke Study I (ECASS I), a double-blind, randomized, multicenter trial. The baseline CT scans were obtained within 6 hours from the onset of symptoms. Functional and neurological outcomes were assessed using the modified Rankin Scale and the Scandinavian Stroke Scale at day 90. Results-We found an HMCAS in 107 patients(17.7%). The initial neurological deficit was more severe in patients with the HMCAS than in those lacking this sign (P

Original languageEnglish
Pages (from-to)769-772
Number of pages4
JournalStroke
Volume30
Issue number4
Publication statusPublished - Apr 1999

Keywords

  • Stroke assessment
  • Stroke outcome
  • Stroke, acute
  • Thrombolytic therapy
  • Tomography, x-ray computed

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Neuroscience(all)

Fingerprint Dive into the research topics of 'Association of hyperdense middle cerebral artery sign with clinical outcome in patients treated with tissue plasminogen activator'. Together they form a unique fingerprint.

Cite this